European Urology Oncology, 6, 2, pp. 214-221 Beijert, I J, Hentschel, A E, Bründl, J, Compérat, E M, Plass, K, Rodríguez, O, Subiela Henríquez, J D, Hernández, V, de la Peña, E, Alemany, I, Turturica, D, Pisano, F, Soria, F, Čapoun, O, Bauerová, L, Pešl, M, Bruins, H M, Runneboom, W, Herdegen, S, Breyer, J, Brisuda, A, Calatrava, A, Rubio-Briones, J, Seles, M, Mannweiler, S, Bosschieter, J, Kusuma, V R M, Ashabere, D, Huebner, N, Cotte, J, Mertens, L S, Claps, F, Masson-Lecomte, A, Liedberg, F, Cohen, D, Lunelli, L, Cussenot, O, el Sheikh, S, Volanis, D, Côté, J-F, Rouprêt, M, Haitel, A, Shariat, S F, Mostafid, A H, Nieuwenhuijzen, J A, Zigeuner, R, Dominguez-Escrig, J L, Hacek, J, Zlotta, A R, Burger, M, Evert, M, Hulsbergen-van de Kaa, C A, van der Heijden, A G, Kiemeney, L A L M, Soukup, V, Molinaro, L, Gontero, P, Llorente, C, Algaba, F, Palou, J, N'Dow, J, Ribal, M J, van der Kwast, T H, Babjuk, M, Sylvester, R J & van Rhijn, B W G 2023, ' Prognosis of Primary Papillary Ta Grade 3 Bladder Cancer in the Non-muscle-invasive Spectrum ', European Urology Oncology, vol. 6, no. 2, pp. 214-221 . https://doi.org/10.1016/j.euo.2023.01.004 European Urology Oncology, 6(2), 214-221. Elsevier BV